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The expression of thyroid hormone transporters in the
human fetal cerebral cortex during early development and
in N-Tera-2 neurodifferentiation
Abstract
Associations of neurological impairment with mutations in the thyroid hormone (TH)
transporter, MCT8, and with maternal hypothyroxinaemia, suggest that THs are crucial for
human fetal brain development. It has been postulated that TH transporters regulate the
cellular supply of THs within the fetal brain during development. This study describes the
expression of TH transporters in the human fetal cerebral cortex (7-20 weeks gestation) and
during retinoic acid induced neurodifferentiation of the human N-Tera-2 (NT2) cell line, in
triiodothyronine (T3) replete and T3-depleted media. Compared with adult cortex, mRNAs
encoding OATP1A2, OATP1C1, OATP3A1 variant 2, OATP4A1, LAT2 and CD98 were
reduced in fetal cortex at different gestational ages, whilst mRNAs encoding MCT8, MCT10,
OATP3A1 variant 1 and LAT1 were similar. From the early first trimester,
immunohistochemistry localised MCT8 and MCT10 to the microvasculature and to
undifferentiated CNS cells. With neurodifferentiation, NT2 cells demonstrated declining T3
uptake, accompanied by reduced expressions of MCT8, LAT1, CD98 and OATP4A1. T3
depletion significantly reduced MCT10 and LAT2 mRNA expression at specific time points
during neurodifferentiation but there were no effects upon T3 uptake, neurodifferentiation
marker expression or neurite lengths and branching. MCT8 repression also did not affect NT2
neurodifferentiation. In conclusion, many TH transporters are expressed in the human fetal
cerebral cortex from the first trimester, which could regulate cellular TH supply during early
development. However, human NT2 neurodifferentiation is not dependent upon T3 or MCT8
and there were no compensatory changes to promote T3 uptake in a T3-depleted environment.
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Non-technical summary 
Thyroid hormones are important in brain development and they enter cells through thyroid 
hormone transporters at the cell membrane. Thyroid hormone transporters are thought to play an 
important role since gene defects in one of these transporters, MCT8, have been associated with 
severe mental retardation. This paper describes the expression of a range of thyroid hormone 
transporters in the human fetal brain during early pregnancy, which suggests that these 
transporters could regulate the supply of thyroid hormones into brain cells from very early in 
development. Surprisingly, the reduction of thyroid hormones and MCT8 expression do not affect 
the differentiation of an unspecialised cell to a specialised human nerve cell in the brain. Thyroid 
hormones and MCT8 are thus likely to affect other processes during human brain development. 
To find out how thyroid hormones influence human fetal brain development requires further 
research. 
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Abstract 
Associations of neurological impairment with mutations in the thyroid hormone (TH) transporter, 
MCT8, and with maternal hypothyroxinaemia, suggest that THs are crucial for human fetal brain 
development. It has been postulated that TH transporters regulate the cellular supply of THs 
within the fetal brain during development. This study describes the expression of TH transporters 
in the human fetal cerebral cortex (7-20 weeks gestation) and during retinoic acid induced 
neurodifferentiation of the human N-Tera-2 (NT2) cell line, in triiodothyronine (T3) replete and 
T3-depleted media. Compared with adult cortex, mRNAs encoding OATP1A2, OATP1C1, 
OATP3A1 variant 2, OATP4A1, LAT2 and CD98 were reduced in fetal cortex at different 
gestational ages, whilst mRNAs encoding MCT8, MCT10, OATP3A1 variant 1 and LAT1 were 
similar. From the early first trimester, immunohistochemistry localised MCT8 and MCT10 to the 
microvasculature and to undifferentiated CNS cells. With neurodifferentiation, NT2 cells 
demonstrated declining T3 uptake, accompanied by reduced expressions of MCT8, LAT1, CD98 
and OATP4A1. T3-depletion significantly reduced MCT10 and LAT2 mRNA expression at 
specific time points during neurodifferentiation but there were no effects upon T3 uptake, 
neurodifferentiation marker expression or neurite lengths and branching. MCT8 repression also 
did not affect NT2 neurodifferentiation. In conclusion, many TH transporters are expressed in the 
human fetal cerebral cortex from the first trimester, which could regulate cellular TH supply 
during early development. However, human NT2 neurodifferentiation is not dependent upon T3 
or MCT8 and there were no compensatory changes to promote T3 uptake in a T3-depleted 
environment.  
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Abbreviations  
AMV, avian myeloblastosis virus; BBB, blood brain barrier; BSA, bovine serum albumin; CNS, 
central nervous system; cpm, counts per minute; D2, iodothyronine deiodinase type 2; D3, 
iodothyronine deiodinase type 3; FBS, fetal bovine serum;  LAT, system-L amino acid 
transporter; MCT, human monocarboxylate transporter; mct, animal monocarboxylate 
transporter; NT2, N-Tera 2 cells; OATP, organic anion transporting polypeptide; TH, thyroid 
hormone; TR, thyroid hormone receptor; T3, triiodothyronine; T4, thyroxine; TBS, Tris buffered 
saline; RA, retinoic acid.  
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Introduction 
The sensitivity of the human fetal central nervous system (CNS) to small reductions in thyroid 
hormone (TH) exposure has been suggested by studies associating maternal subclinical 
hypothyroidism and hypothyroxinaemia with long-term neurodevelopmental deficits in offspring 
(Haddow et al., 1999;Pop et al., 2003). Current evidence suggests a direct effect of maternal THs 
upon fetal CNS development, particularly in the first half of pregnancy before the onset of 
endogenous fetal TH production (de Escobar et al., 2004). In rodents, THs are known to affect the 
proliferation and differentiation of CNS cells (Jones et al., 2003;Garcia-Silva et al., 2002), 
neuronal migration (Lavado-Autric et al., 2003), synaptogenesis (Gilbert & Paczkowski, 2003) 
and dendritic branching (Heuer & Mason, 2003). These effects are mostly mediated by nuclear 
TH receptors (TRs), that bind the active TH ligand, triiodothyronine (T3), to influence TH-
responsive gene transcription. 
Whilst circulating THs are the major determinants of TH supply, effective TH action requires the 
uptake of THs into cells and pre-receptor regulation of local T3 bioavailability by iodothyronine 
deiodinases. It is postulated that astrocytes express deiodinase type 2 (D2) that activates 
circulating thyroxine (T4) to T3 locally. Subsequently, T3 is transported into neurons, these cells 
being the ultimate target for TH action and shown to express TRs (Kilby et al., 2000) and 
deiodinase type 3 (D3), which inactivates any excess T3 (Tu et al., 1999).  
Specific transport mechanisms facilitate the cellular influx and efflux of THs (Hennemann et al., 
2001). TH transporters are required for TH passage across the blood brain barrier (BBB), choroid 
plexus and into neuronal and glial cells. Interest has focused on monocarboxylate transporter 8 
(MCT8), whose gene mutations in humans have been associated with severe global neurological 
impairment including psychomotor, speech and cognitive deficits with radiological evidence of 
cortical and subcortical atrophy, alongside elevated serum free T3 but normal or low free T4 
concentrations (Dumitrescu et al., 2004;Friesema et al., 2004;Schwartz et al., 2005). Post-mortem 
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examination of an affected boy has revealed loss of neurons in the cerebral cortex, cerebellum 
and basal ganglia (Dumitrescu et al., 2004).  
TH transport has also been demonstrated by monocarboxylate transporter 10 (MCT10), several 
organic anion transporting polypeptides (OATP) and System-L amino acid transporters (LAT). 
They have slightly different affinities for THs and transport other compounds (Table 1). Their 
expressions have been described in human adult brains and rodent brains but there have been few 
studies of the early human fetal brain.  
It has been hypothesised that the regulation of cellular TH entry by TH transporters is critical to 
timely TH action during human fetal brain development, particularly neurodevelopment. We 
have, therefore, investigated changes in the expression of TH transporters within the human fetal 
cerebral cortex during the first half of gestation and during the neurodifferentiation of N-Tera-2 
(NT2) cells, a human pluripotent embryonal cell line with characteristics of CNS precursors, 
which can be terminally differentiated into functional neurons (Andrews et al., 1984). We 
assessed if compensatory changes in TH transporter activity occurred with T3-depletion and, 
specifically, if MCT8 expression is important in NT2 neurodifferentiation. 
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Materials and Methods 
Ethical Approval 
All tissue samples were obtained with the approval of the East Birmingham and South 
Birmingham Local Research and Ethics Committees, with written parental consent, and within 
the terms of the New Human Tissue Act, UK (2004) and the Declaration of Helsinki. 
Human Tissues 
Sixty-five human fetuses of gestational ages between 7 and 20 post-menstrual weeks (weeks) 
were examined after surgical termination of pregnancy and cerebral cortices biopsied as 
previously described (Chan et al., 2002;Kilby et al., 2000). In brief, the fetal cortex was identified 
at operation and a biopsy taken as histological evaluation of paraffin embedded sections, and 
further samples snap frozen immediately in liquid nitrogen. Fetuses were grouped thus: early 1st 
trimester 7-9 weeks (n=11), late 1st trimester 10-12 weeks (n=25), early 2nd trimester 13-16 weeks 
(n=20) and mid 2nd trimester 17-20 weeks (n=9). In addition, samples of normal adult cerebral 
cortex (n=10) taken at post-mortem and donated to the UK National Brain Bank were obtained 
(The Institute for Neurological Diseases, Queen’s Square, London, UK). All samples were snap-
frozen in liquid nitrogen and stored at -80°C until required for RNA and protein evaluation. 
RNA extraction, reverse transcription and real time quantitative TaqMan® PCR 
Total RNA was extracted from 100mg frozen tissue after homogenisation, using TRIagent 
(Sigma, Poole, UK), as described previously (Chan et al., 2002). RNA (1g) was reverse 
transcribed using avian myeloblastosis virus (AMV) reverse transcriptase (Promega Corp., 
Madison, WI, USA) in a total reaction volume of 20l, with random hexamer primers according 
to manufacturer’s instructions then diluted 1:2 with RNAse free water. 
RT-PCR was carried out in 25l reactions on 96-well plates in a reaction buffer containing 1X 
TaqMan® Universal PCR Master Mix, 150 nmol TaqMan® probe and 900 nmol primers using 
the ABI PRISM 7500 Sequence Detection System, as described previously (Chan et al., 2002). 
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Primers and FAM-labelled probe sets for all genes were as previously validated and described 
(Chan et al., 2006;Loubiere et al., 2010) except for OATP3A1 variants 1 and 2, which were 
newly designed with Primer Express v3.0 (Applied Biosystems) (Table 2) and validated alongside 
control RT reactions without AMV. To provide an internal reference for RT efficacy, 18S 
ribosomal RNA and cyclophilin VIC-labelled-probes and primers (Applied Biosystems, 
Warrington, UK) were selected for normalisation based upon preliminary tests using the 
TaqMan® Human Endogenous Control Array plate (Applied Biosystems, Warrington, UK) and 
model-based calculations as previously described (Andersen et al., 2004). All reactions were 
performed single-plexed in duplicate. Relative quantifications of each gene were determined, as 
previously described (Loubiere et al., 2010), and normalised to the geometric means of the two 
control genes. The mean mRNA expression for adult samples was assigned the arbitrary value of 
1. The relative mRNA expression for each sample compared to the mean for adults was 
calculated and used to perform statistical analysis. 
Immunohistochemistry 
Formalin-fixed paraffin-embedded sections (5μm) of forebrain (telencephalon) from three 
surgically terminated pregnancies between 8 and 11 weeks gestation were obtained from the 
London Neurogenerative Disease Brain Bank (Institute of Psychiatry, King’s College London). 
Sections were immunostained for MCT8 or MCT10 using an avidin-biotin peroxidase technique 
(Vectastain Elite, Vector Laboratories, Peterborough, UK) as we have previously described 
(Kilby et al., 2000;Boelaert et al., 2003). Briefly, after de-waxing with Histoclear and serial 
rehydration with ethanol, sections were incubated in 10mM sodium citrate buffer (pH 6.0) at 95ºC 
for 5 minutes for antigen retrieval. After washing in 50mM Tris/0.15M saline (pH 7.5; TBS), the 
sections were blocked with 10% normal goat serum (Sigma-Aldrich, UK) in diluting buffer (TBS, 
0.3%Tween 20, 2%BSA) for 20 minutes before incubation overnight at 4ºC with the primary 
antibody MCT8 (1:800) or MCT10 (1:800). The manufacture and specificity of the MCT8 (4790) 
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(Loubiere et al., 2010), MCT10 (2198) antibodies (Vasilopoulou et al., 2010) [Figure 1C and 1D] 
have been previously described. Specificity of immunostaining was further confirmed using 
adjacent sections as negative controls treated with the primary antibody pre-absorbed by an 
excess of blocking peptide. With TBS-Tween washes between each step, the sections were 
incubated with biotinylated goat anti-rabbit secondary antibody (1:200; Vector Laboratories, UK) 
for 30 minutes, followed by 5% hydrogen peroxide in TBS (5 minutes), then avidin-biotin-
peroxidase complex application (30 minutes) and developed by incubation in 3,3’-
diaminobenzidine (Vector Laboratories, UK) for 5-15 minutes. Sections were rinsed in distilled 
water and mounted in Vectashield mounting media (Vector Laboratories, UK).  
Neurodifferentiation of NT2 cells 
NT2 cells (European Collection of Cell Cultures, Salisbury, UK) were maintained in 
DMEM:Hams F12 (1:1) Dulbecco’s growth medium supplemented with 10% (v/v) fetal bovine 
serum (FBS), 2mM L-glutamine and 100U/ml of penicillin/streptomycin (Invitrogen Ltd., UK) as 
previously described (Andrews et al., 1984). Cells were passaged and split 1:4 twice weekly, and 
cultured at 37oC and 5% CO2. Differentiation of NT2 precursor cells to terminally 
differentiated neurons with retinoic acid (RA) treatment was conducted based on methods 
previously described (Pleasure et al., 1992;Chan et al., 2003). Charcoal-stripped FBS (First Link 
Ltd., UK), which is virtually devoid of THs, was used to create a T3-depleted environment. Since 
NT2 cells were unable to tolerate 5 weeks in culture with media supplemented with charcoal-
stripped FBS alone, differentiation experiments were performed in media containing 2% of 
normal FBS with 8% of charcoal-stripped FBS (combination media) with the addition of 10nM 
T3 (T3-replete) and without T3 (T3-depleted) along with 10µM RA (Sigma-Aldrich, UK). We 
had previously shown that the dose of 10nM T3 was optimal in the induction of T3-responsive 
gene expression in NT2 cells (Chan et al., 2003). 
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Quantitative RT-PCR  
At time 0, 1, 3, 7, 14 and 21 days after RA treatment (n=6 experiments, each condition in 
duplicate), total RNA was extracted and reverse transcribed for real time quantitative RT-PCR 
performed as described above. These time points were chosen based on when significant 
differences in neurodifferentiation marker expression in NT2 cells has been previously described 
(Przyborski et al., 2003). Primers and FAM-labelled probes for the neurodifferentiation markers: 
Pou5F1, nestin, neurofilament-light, were designed and validated (Table 2). All reactions were 
performed single-plexed along side VIC-labelled-probe and primers for 18S ribosomal RNA 
(Applied Biosystems, Warrington, UK) as an internal reference. Relative mRNA expression was 
calculated as above within each experiment with the mean expression at time 0 assigned the 
arbitrary value of 1.  
Western blotting and Flow cytometry 
Protein was extracted on Days 0, 3, 7 and 14 (n=4 experiments) using RIPA buffer (150 mM 
sodium chloride, 1% Triton X-100, 1mM EDTA, 0.25% sodium deoxycholate and 50 mM Tris, 
pH7.4) with protease inhibitors then quantified (Bradford assay). Western immunoblotting was 
performed as we have previously described (Boelaert et al., 2003;Loubiere et al., 2010). Protein 
(30µg) was denatured (30 min at 37°C or 95°C ) in Laemmli buffer containing DTT and 1% SDS, 
then separated by electrophoresis in 8% or 10% SDS-PAGE gel and blotted onto nitrocellulose 
membranes. Blots were incubated in 5% non-fat milk in 20mM Tris/137mM NaCl, Tween 
0.025% (TBS-Tween; pH 7.6) then probed with primary antibody overnight. The manufacture 
and specificity of the OATP antibodies have also been previously described (Huber et al., 
2007;Gao et al., 2005). Rabbit polyclonal primary antibodies were used at 1:500 for MCT8, 
1:250 for MCT10, 1:1000 for OATP3A1v1, OATP3A1v2 and OATP4A1 and goat polyclonal 
anti-human CD98 (SantaCruz, California, USA) at 1:250. Following washes with TBS-Tween 
immunoblots were then probed with secondary antibody conjugated to horseradish peroxidase 
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and bands visualised using the ECL Plus chemiluminescence detection kit (GE Healthcare Life 
Sciences). ß-actin expression was used to assess protein loading. Relative densitometry was 
performed using the Image J soft ware (NIH, USA). Given the specific interest in MCT8, we also 
used flow cytometry to quantify MCT8 protein at time 0, 1, 3, 7, 14 and 21 days after RA 
treatment (n=3 experiments). Cells were detached with 5mM EDTA, fixed in 4% 
paraformaldehyde (10 minutes at 37ºC), permeabilized with ice cold 90% methanol (30 minutes), 
blocked with 5% normal goat serum then stained with anti-MCT8 (1:100) followed by goat-anti-
rabbit-FITC (1:500; Abcam plc. Cambridge, UK). Staining and washes were performed in 1% 
FBS in PBS at room temperature. Cell fluorescence was acquired on a BectonDickinson 
FACSCalibur multicolour flow cytometer with the CellQuest software (BD Biosciences, MD, 
USA) and analysed with the FlowJo software (Tree Star Inc, OR, USA).  
T3 uptake experiments 
T3 uptake by NT2 cells was measured in duplicate at time points coinciding with 
neurodifferentiation marker assessments which were following 0, 1, 3, 7, 14 and 21 days culture 
with RA in T3-replete or T3-depleted media in 12-well plates. Following a 1 hour wash out in 
combination media, cells were incubated for 0, 2, 10 or 30 minutes with serum free medium 
supplemented with 1nM T3 containing approximately 1.5x105 cpm of [125I]T3 (Perkin Elmer, 
Massachusetts, USA) then rapidly washed three times with ice-cold serum free medium 
containing 0.1% BSA and lysed with 2% SDS. The radioactivity in the cell lysates (intracellular 
radioactivity) were expressed as a percentage of the radioactivity in the incubation media and 
corrected for total protein content quantified by the Bradford assay (Friesema et al., 2008;James 
et al., 2009). 
Morphological assessments of differentiated neurons 
To isolate fully differentiated neurons, cells were RA treated three times a week for 5 weeks then 
replated in fresh combination media without RA for 48 hours. This conditioned media was 
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subsequently stored for use later in the experiment. Cells were then fed with combination media 
containing 10M 5-Fluoro-2’-deoxyuridine (FudR), 10M Uridine (Urd) and 1M Cytosine -D-
Arabinofuranoside (araC) (Sigma-Aldrich, UK) four times over 9-10 days followed by a single 
feed of conditioned media without mitotic inhibitors for 24 hours, as previously described 
(Pleasure et al., 1992;Chan et al., 2003). Differentiated neurons were detached by mechanical 
tapping and plated onto poly-D-lysine and laminin (Sigma-Aldrich, UK) coated chamber slides 
(0.9cm2) then passaged in 50:50 conditioned media (i.e. equal amounts of combination and 
conditioned media) every 3-4 days for one week, to yield a purer population of neurons. Neurons 
were fixed in 4% formaldehyde, blocked with 5% goat serum plus 0.1% Triton X-100 and 
immunostained with 3-tubulin (1:200; Sigma-Aldrich, UK) followed by Alexa Fluor® 488 goat 
anti-rabbit  (1:1000; Invitrogen, UK) and mounted with Vectashield with DAPI (Vector 
Laboratories, UK). Neurons were examined under an epifluorescent microscope (Zeiss) and 
neurite outgrowth analysed using an image analysis software (Axiovision 4.0, Carl Zeiss, USA). 
Individual neurons with clearly visible neurites in their entirety were analysed for the length of 
the longest primary neurite, the total length of all primary neurites, total number of primary 
neurites per neuronal body and number of secondary neurites measuring greater than 20M in 
length (Ahmed et al., 2005). Fifteen non-overlapping high-powered fields per well (n=7 wells for 
each condition) obtained over two separate differentiation experiments were assessed with 
measurements obtained for a total of 83 neurons in a T3-depleted environment and 43 neurons 
with T3-repletion. Average results for each well were used for statistical analysis. 
Repressing MCT8 expression using siRNA 
MCT8 knock-down experiments were carried out using predesigned MCT8-specific siRNAs 
(ID#117397, Ambion Inc., Huntingdon, UK) as previously described (James et al., 2009). A 
‘scrambled’ siRNA (siRNA #1, ID#4611, Ambion Inc., Huntingdon, UK) was used as negative 
control. NT2 cells were transfected using siPORT NeoFX transfection reagent (Ambion Inc., 
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Huntingdon, UK) as per manufacturer’s instructions. In brief, cells were trypsinized and 
suspended in culture media and mixed with siRNA (10 nM) and NeoFX transfection reagent (4 
µl/ml of medium) before plating and incubation for 48 hours prior to RA treatment in T3-replete 
or T3-depleted media. Total RNA and protein were harvested on Days 0, 1, 3, 7, 14 and 21 after 
RA treatment and assessed by TaqMan® RT-PCR and western immunoblotting respectively (as 
described above) to confirm the silencing of endogenous MCT8 (n=4 experiments). Messenger 
RNA expression of the neurodifferentiation markers Pou5F1, nestin and neurofilament-light were 
quantified by TaqMan® RT-PCR as described above. We had previously confirmed that MCT8 
repression by MCT8-specific siRNAs resulted in a significant reduction in T3 uptake by 19% at 
72 hours post-transfection compared with ‘scrambled’ controls (James et al., 2009). 
Statistical Analyses 
Data were analysed using Sigma Stat software version 3.1 (SPSS Science Software UK Ltd). For 
the ontogeny data, the Kruskal-Wallis ANOVA was used for between group comparisons with 
Dunn’s post-hoc multiple comparisons testing to isolate groups that differed from others. For the 
NT2 cell work, data were analysed by the general linear model repeated measures ANOVA 
taking into account all variables with Tukey post-hoc multiple comparisons analysis. Data from 
the MCT8 knock-down experiments required logarithmic transformation to pass normality tests 
as determined using the Kolmogorov-Smirnov test prior to analysis of variance. Significance was 
accepted as P<0.05.  
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Results 
Expression of TH transporters in the human fetal cerebral cortex 
Monocarboxylate Transporters (MCTs) 
The levels of mRNA encoding both MCT8 and MCT10 did not demonstrate any statistically 
significant differences in the fetal cerebral cortex across gestation (7 to 20 weeks) and when 
compared with adult (Figure 1A, 1B).  
The presence of both MCT8 and MCT10 protein from early gestation was confirmed by 
immunohistochemistry (Figures 1E-F). MCT8 was localised within the microvasculature and in 
undifferentiated CNS precursor cells within the fetal cerebral cortex from 8 weeks with similar 
localisation at 11 weeks. MCT10 staining was evident in undifferentiated CNS cells and 
occasionally in early differentiated neurons, recognisable by a short axonal process emanating 
from the perikaryon, at 8 weeks but there were a reduced proportion of undifferentiated cells 
staining positive at 10 weeks. In contrast to MCT8, faint but clear MCT10 staining of the 
microvasculature was only observed at 10 weeks gestation but not at 8 weeks. For both MCT8 
and MCT10 only a subpopulation of undifferentiated cells clearly stained positive, which could 
represent particular stages of neuronal or glia development. No immunostaining was observed 
with pre-absorption of the primary antibody with the respective blocking peptides.  
Organic Anion Transporting Polypeptides (OATPs) 
Messenger RNAs encoding OATP1A2, OATP1C1 and OATP3A1v2 were significantly lower in 
the fetal cerebral cortex compared with adults (ANOVA P<0.001 for each, Figures 2A-C) with 
mean expression at 7-9 weeks being 92%, 96% and 95% lower than adults’ respectively 
(P<0.05). Whilst the mean levels of OATP1A2 and OATP1C1 mRNAs remained significantly 
lower until 16 weeks of gestation and began to increase in mid-gestation at 17-20 weeks, the 
mean level of OATP3A1v2 mRNA expression remained suppressed at 97% even at 17-20 weeks 
compared with adult (P<0.05). In contrast, OATP3A1v1 mRNA expression in the fetal cerebral 
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cortex from 7 to 20 weeks was similar to adult (Figure 2D). Mean OATP4A1 mRNA expression 
(ANOVA P<0.05) was similar to adult levels in the early 1st trimester but dropped to a nadir at 
10-12 weeks, reaching a 70% reduction compared with adult (P<0.05), then subsequently 
increased to adult levels by mid-gestation (Figure 2E). 
System L-type amino acid transporters (LATs and CD98) 
Messenger RNA encoding LAT1 did not show any statistically significant differences in 
expression in the fetal cerebral cortex between 7 to 20 weeks and when compared with adult 
(Figure 3A). In contrast, both LAT2 (ANOVA P<0.01) and the LATs’ obligatory associated 
protein, CD98 (ANOVA P<0.05), demonstrated a significant decrease in mRNA expression in 
the fetal cerebral cortex at 17-20 weeks with a 92% and 82% reduction in mean expression 
respectively compared with adult (P<0.05; Figures 3B and 3C). LAT2 mRNA expression at 17-
20 weeks was also significantly lower compared with that at 10-12 weeks and 13-16 weeks 
(P<0.05).  
Expression of TH transporters and response to T3 during NT2 neurodifferentiation 
With the localisation of MCT8 and MCT10 in CNS precursor cells and neurons being the 
postulated ultimate target cell of T3 action in the brain during development, we went on to 
investigate human neurodifferentiation in vitro using human CNS precursor NT2 cells, which 
express the TR isoforms, 1, 2 and 1, and are T3-responsive. They demonstrate increased 
mRNA expression of the thyroid hormone responsive gene, TR1 (Chan et al., 2003), and 
increased cell proliferation in response to T3 treatment (James et al., 2009).  
T3 does not affect NT2 neurodifferentiation 
The changes in mRNA expression of three neurodifferentiation markers, Pou5F1, nestin and 
neurofilament, across 21 days of RA treatment (Figure 4A-C) were consistent with that 
previously described in NT2 cells (Przyborski et al., 2003) and were similar for NT2 cells 
differentiated in T3-depleted compared with those in T3-replete media. Pou5F1 mRNA 
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expression was significantly down-regulated by Day 1 (P<0.01) compared with Day 0 with 
further reductions on Day 3 and Day 7, then remained suppressed at Days 14 and 21 (P<0.001; 
Figure 4A). Nestin mRNA expression peaked on Day 3 (P<0.05) followed by a significant 
reduction by Day 7 (P<0.001) after RA treatment which was sustained until Day 21 (Figure 4B). 
Neurofilament mRNA showed a gradual rise in expression showing significantly increased 
expression on Day14 and 21 by 7-fold (P<0.05) and 11-fold (P<0.001) respectively compared 
with Day 0 (Figure 4C). The morphology of neurons assessed by measuring the lengths of 
primary neurites and counting the number of primary neurites and branch points (ratio of the 
number of secondary neurites to the number of primary neurites per neuron) showed no 
significant differences between neurons terminally differentiated in T3-depleted media compared 
with T3-repletion (Figures 4D-E). 
TH transporter expression with NT2 neurodifferentiation 
We then investigated if the lack of effect of T3-depletion upon NT2 neurodifferentiation was due 
to compensatory up-regulation in TH transporter expression and function. Only two TH 
transporters, MCT10 and LAT2 demonstrated significant changes in expression when NT2 cells 
were differentiated in T3-depleted media compared with those in T3-replete media (ANOVA  for 
effect of T3 were P<0.05 for both; Figures 5A-B). However, contrary to our hypothesis, T3-
depletion resulted in time-specific suppression in mRNA expression: MCT10 on Days 1 (P<0.05) 
and 14 (P<0.001) and LAT2 on Day 14 (P<0.01). None of the other thyroid hormone transporters 
demonstrated alterations in expression with T3 depletion. 
With RA-induced neurodifferentiation, the TH transporters displayed four different patterns of 
changes in mRNA expression. Firstly, MCT10 and LAT2 mRNA expression demonstrated a 
nadir on Days 3 and 7 (ANOVA for effect of time were P<0.001 for both; Figures 5A-B). 
MCT10 protein expression assessed by Western blotting, however, did not show any statistically 
significant changes with RA treatment nor with T3 treatment (data not shown). Secondly, there 
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was a zenith in OATP3A1v2 mRNA expression on Days 7 and 14 of RA treatment (ANOVA 
P<0.01; Figures 5C). In the third group, MCT8 mRNA declined significantly (ANOVA P<0.01; 
Figure 5D) from Day 3 to Day 14 (P<0.01) whilst OATP4A1 (ANOVA P<0.01; Figure 5E) and 
LAT1 (ANOVA P<0.001; Figure 5F) mRNA declined significantly from Day 1 to Day 7 then all 
remained suppressed until Day 21. MCT8 protein assessed by flow cytometry was already 
significantly down-regulated by Day 3 compared to Day 0 and remained suppressed (ANOVA 
P<0.001; Figure 4G). However, OATP4A1 protein assessed by Western blotting showed no 
statistically significant changes (data not shown). In the final group, CD98 and OATP3A1v1 
mRNA expression remained unchanged throughout the course of RA treatment (data not shown) 
but CD98 protein assessed by Western blotting was significantly down-regulated by Day 7 
compared to Day 3 (ANOVA P<0.01; Figures 4H-I). Since CD98 is the obligatory associated 
protein of the System-L transporters, CD98 down-regulation could reduce the activities of both 
LAT1 and LAT2. NT2 cells did not express OATP1C1 mRNA. 
T3 uptake by NT2 cells during neurodifferentiation 
To assess the combined effects of the TH transporters upon net T3 uptake over the course of RA 
induced neurodifferentiation, comparisons of T3 uptake were made from data obtained after 10 
minutes of incubation in [125I]T3. There was a significant decline of 52-55% in T3 uptake 
between Day 0 compared with Days 7 and 14 of RA treatment (P<0.05 for both; Figure 5J). 
However, no differences in T3 uptake were observed between cells cultured in T3-depleted media 
compared with T3 replete media at 2, 10 and 30 minutes after incubation in [125I]T3 (only data at 
10 minutes are shown in Figure 5J). 
MCT8 repression does not affect NT2 neurodifferentiation 
Given the association of MCT8 mutations with severe neurological impairment, that MCT8 
represses NT2 proliferation independently of T3 (James et al., 2009), that early overexpression of 
Mct8 in murine embryonic stem cells can accelerate neurodifferentiation (Sugiura et al., 2007) as 
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well as this study’s findings of MCT8’s localisation in undifferentiated CNS cells in the human 
fetal brain and a down-regulation of MCT8 with neurodifferentiation, we hypothesised that 
MCT8 plays a critical role during early NT2 neurodifferentiation. Thus, we proceeded with 
MCT8 knock-down prior to RA treatment. At the start of RA treatment (Day 0), significant 
repression in the mRNA and protein expression of endogenous MCT8 in NT2 cells was already 
achieved, with a 72% reduction in MCT8 mRNA expression in MCT8-specific siRNA transfected 
cells compared with cells transfected with scrambled siRNA (P<0.00001; Figure 6A). This 
significant reduction in MCT8 mRNA expression was sustained at least until Day 3 and 
accompanied by suppression of both MCT8 monomer and homodimer protein expression (Figure 
6B). By Day 7, there was still some suppression in MCT8 monomer protein expression but the 
homodimer expression was now similar to controls. Repression of MCT8 expression did not, 
however, result in any significant changes in the mRNA expression of the neurodifferentiation 
markers Pou5F1, nestin and neurofilament both in T3-replete and T3-depleted media (Figures 6C-
E). 
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Discussion 
This study describes for the first time the ontogeny of nine different TH transporters 
simultaneously in a series of human fetal cerebral cortex samples from the first half of pregnancy. 
The presence of MCT8, OATP1C1, OATP1A2, OATP4A1, LAT1 and LAT2 is consistent with 
previous reports based on studies of the human fetal brain at later gestations (Table 1). 
Descriptions of the expression of OATP3A1 (variants 1 and 2) and MCT10, and the localisation 
MCT8 and MCT10 within the human fetal cerebral cortex in the 1st trimester of pregnancy are 
novel. Even though NT2 cells express multiple TH transporters and demonstrate T3 uptake, T3 
and specifically MCT8 are not critical for NT2 neurodifferentiation.  
Minor aberrations in maternal thyroid function occurring before the onset of endogenous fetal TH 
production in the midtrimester of human pregnancy are associated with long-term 
neurodevelopmental sequelae in offspring (Haddow et al., 1999;Pop et al., 2003). The mechanism 
by which this occurs is speculatively through the inadequate supply of transplacentally-derived 
maternal TH, which can directly impact upon the early developing fetal CNS. Maternally-derived 
T4 can already be found at biologically relevant concentrations in the coelomic and amniotic 
fluids from 5 weeks (Calvo et al., 2002). The expression of multiple TH transporters from 7 
weeks suggests that CNS cells have the capability for TH uptake from the early 1st trimester. 
These findings taken together with our previous data showing that human fetal cerebral cortices 
express all of the major TR isoforms and display D2 and D3 activities from 7 weeks (Chan et al., 
2002) support the notion that the early developing human CNS possesses all of the necessary 
apparatus for TH uptake, metabolism and utilisation. Indeed in a rat model, the impact of a 
significant rise in maternal T4 upon TH responsive gene expression has been demonstrated within 
the fetal brain before endogenous fetal TH production (Dowling et al., 2000). Our data support 
the hypothesis that the human fetal brain can respond to maternal TH from as early as 7 weeks, 
which could influence human CNS development. 
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Using Mct8 knockout mouse models, Mct8 has been shown to play an important role in TH entry 
across the BBB (Ceballos et al., 2009), the main route of TH entry into the brain (Dratman et al., 
1991), and into CNS neurons (Trajkovic et al., 2007;Wirth et al., 2009). Thus, in human subjects 
with a MCT8 mutation, impaired cerebral TH uptake is very likely to contribute to the severe 
neurological phenotype described (Heuer, 2007). This suggests the importance of TH transporters 
in the regulation of both the entry of TH into brain parenchyma as well as across the plasma 
membranes of neuronal cells. The localisation of MCT8 and MCT10 in the microvasculature and 
in undifferentiated CNS cells in the1st trimester human fetal cerebral cortex supports this notion 
and emphasizes the possible early role played by these transporters in human cortical 
neurogenesis, which begins at 6 weeks and continues into midgestation with evidence of 
heterogeneity of progenitor cells in the entire telencephalic wall through out this time (Howard et 
al., 2006). 
Changes in the expression of the TH transporters across gestation may reflect developmental 
regulation in response to rising TH availability with advancing gestation (Kester et al., 2004) and 
to altering cellular need for TH within specific cell types and brain regions, as well as reflect their 
role in the transport of other compounds apart from THs. The 17-20th week of gestation appears to 
be a watershed for TH transporter mRNA expression, which coincides with onset of endogenous 
fetal TH production (de Escobar et al., 2004) and the formation of anatomically-continuous 
effective endothelial tight junctions in the BBB (Virgintino et al., 2004). Both OATP1A2 and 
OATP1C1, which are largely confined to endothelial cells forming the BBB in the human 
cerebral cortex (Gao et al., 2000;Bronger et al., 2005;Roberts et al., 2008), show very low mRNA 
expression in the fetal brain and only begin to rise from 17-20 weeks, the time when transcellular 
transport of proteins across the BBB is required. Possible increased TH availability at 17-20 
weeks may also signal the need for added regulation at the plasma membrane of neurons and 
glia. This may be reflected by a significant reduction in mRNA encoding CD98 and LAT2, 
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which have been localised to human fetal microglia (Wirth et al., 2009) and in rat neurons and 
astrocytes (Heckel et al., 2003). The contrasting mRNA expression patterns of the splice variants 
of OATP3A1 may reflect their differential role during development and is suggested by their 
differential distribution in the adult cerebral cortex: OATP3A1v1 in grey matter astrocytes and 
OATP3A1v2 in grey and white matter neurons (Huber et al., 2007).  
The variation in mRNA abundance between subjects, even within the same gestational age group, 
is partly attributable to slightly different brain areas being sampled. However, the strength of our 
study is the large numbers of fetal cortices being analysed, which could partially compensate for 
these variations and allow ontogenic patterns to emerge. Even for adult samples, which were 
biopsied from a similar area of the cortex, large variations in mRNA expression of some 
transporters are still present and this may be due to genuine biological variation. 
The expression of multiple transporters in the fetal brain may suggest redundancy in TH-uptake 
mechanisms but the severe neurological phenotype in individuals with an isolated non-functional 
MCT8 mutation implies the contrary argument. It has been postulated that very low OATP1C1 
expression in the BBB and the lack of LAT2 expression in developing neurons cannot 
compensate for the lack of MCT8 function in humans unlike in rodents where there is higher 
Oatp14 (rodent equivalent of OATP1C1) expression at the BBB (Roberts et al., 2008) and co-
expression of Lat2 in Mct8-expressing neurons (Wirth et al., 2009), which may explain why Mct8 
knockout mice show limited neurological impairment (Wirth et al., 2009). If any compensation 
occurs, it is incomplete since primary neurons isolated from Mct8 knockout mice still 
demonstrate reduced T3 uptake compared to wild-type (Wirth et al., 2009). As yet, studies 
comparing the relative expressions of the other TH transporters in wild-type and Mct8 knockout 
mice brains have not been reported. However, it has been demonstrated that local D2 activity 
can compensate for the lack of T3 availability in Mct8 knockout mice brain resulting in limited 
effects on TH responsive gene expression (Morte et al., 2010). 
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To assess the potential roles of the different TH transporters in human neuronal development and 
the possible compensatory effects with T3-depletion, we have used NT2 cells as a human CNS 
precursor model to focus specifically on neurodifferentiation. T3 has a pro-proliferative effect in 
NT2 cells (James et al., 2009), which express TRs and display D3 activity and minimal D2 
activity but deiodinase activities do not change with T3 treatment (Chan et al., 2003). Our finding 
that T3 uptake declines with neurodifferentiation, suggests that T3 may be more important in the 
maintenance of undifferentiated NT2 cells and during the earlier part of neurodifferentiation. 
Decreasing T3 uptake accompanied by the decline in MCT8, LAT1, CD98 and OATP4A1 
expression with neurodifferentiation suggest that these may be the TH transporters regulating T3 
uptake in NT2 cells. Further experiments using inhibitors of these specific TH transporters would 
be required to confirm this postulation.  
When cultured in T3-depleted media, NT2 cells did not demonstrate any compensatory rises in 
TH transporter expression nor in T3 uptake ability despite the absence of compensatory changes 
in deiodinase activities for intracellular T3 regulation. In fact, T3 depletion was associated with 
the suppression of MCT10 and LAT2 mRNA expression. Functional coordination of MCT10 and 
LAT2 activities may occur in the regulation of neutral amino acid efflux by early renal proximal 
tubules (Ramadan et al., 2007). The same could be occurring during neurodifferentiation under 
T3 regulation. The regulation of TH transporter expression by TH has been described in only a 
limited number of studies and appears to vary between transporters and tissue types. In rabbit 
euthyroid sick syndrome that is characterised by a low circulating T3 and low hypothalamic T4, 
Mct8 expression was unaltered but Mct10 and Oatp1C1 expression were increased in the 
hypothalamus (Mebis et al., 2009). In hypothyroid postnatal mice Mct8 mRNA expression is 
upregulated in the femur, and in a mouse osteoblastic cell line, T3 treatment downregulated Mct8 
expression (Capelo et al., 2009). However, no alteration in Lat1 and Lat2 mRNA expression was 
observed in vivo or in vitro in this model.  
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In NT2 cells trends in TH transporter mRNA expression were not always reflected by trends in 
protein expression. Post-transcriptional modulation is likely to be involved and such 
discrepancies have been reported in plasma membrane transporters such as MCT8 in human 
placenta (Loubiere et al., 2010) and Oats in rat kidney (Zlender et al., 2009), although 
mechanisms remain unknown. 
The lack of difference in the rate of neurodifferentiation and neuronal morphology between the 
T3-depleted and T3-replete cells suggests that NT2 neurodifferentiation is not a T3-responsive 
process. Our findings challenge the prevailing notion that THs are critical to neurodifferentiation, 
conclusions which have been based upon research in rats and mice, predominantly on cerebellar 
neurons (Horn & Heuer, 2010). One study of non-CNS derived human fetal olfactory 
neuroepithelium did, however, demonstrate increased neurofilament-M expression assessed by 
immunocytochemistry in response to T3 treatment (Benvenuti et al., 2008) which is in contrast to 
NT2 cells. Apart from the fact that the Mct8 knockout mice show hardly any neurological deficits 
unlike humans, the mouse and rat cerebral cortex also differs from humans in that they 
demonstrate deiodinase type 1 (D1) activity (Visser et al., 1982), which can activate circulating 
T4 into T3, whilst human brains show no D1 activity (Chan et al., 2002). Thus, findings of TH 
action and metabolism in rodent CNS cannot readily be extrapolated to the human situation. 
Since MCT8 also has T3-independent anti-proliferative effects (James et al., 2009), we 
specifically assessed the effects of MCT8 repression in NT2 neurodifferentiation. The absence of 
any changes in neurodifferentiation marker expression, despite significant MCT8 repression, 
suggests that MCT8 does not play a critical role in NT2 neurodifferentiation either. Mct8 has 
been shown to accelerate the neurodifferentiation of murine ES cells (Sugiura et al., 2007) and 
RA has been reported to stimulate Mct8 expression in murine F9 embryonal carcinoma cells 
(Kogai et al., 2010) but NT2 cells display neither of these phenomena, which may be indicative 
of yet more differences in neurodevelopment between mice and humans. 
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From these experiments of NT2 cell culture in isolation, we cannot exclude the possibility that in 
the presence of supportive glial cells, NT2 cells may respond differently to T3 or that possible T3 
effects upon glial cells may indirectly impact upon NT2 neurodifferentiation. Also, charcoal-
stripped FBS lacks some steroidal hormones, which may influence neurodifferentiation. None-
the-less, many in vitro and animal transplant studies support the view that NT2 cells are true 
representations of CNS neuronal progenitor cells (Trojanowski et al., 1997). Transplantation of 
NT2 cells into animal models of neurological disorders have shown benefit and phase II clinical 
trials of NT2 transplantation into human stroke patients are underway (Hara et al., 2008).  
Since there is a lack of effect of T3 and MCT8 upon NT2 neurodifferentiation, it is conceivable 
that the neurological impairment seen in boys with MCT8 mutations is not a direct result of 
defective neurodifferentiation of cerebral neuroprogenitor cells. Apart from increased cerebral TH 
uptake at the BBB (Ceballos et al., 2009) and suppressed neuronal precursor proliferation (James 
et al., 2009), the impact of MCT8 upon other developmental processes within the human fetal 
brain such as neuronal cell transmission activity, synaptogenesis, neuronal migration and glia 
differentiation, remain to be investigated. 
In conclusion, our demonstration of different expression patterns amongst the TH transporters in 
the human fetal cerebral cortex from very early gestation suggests that their concerted actions 
may result in the timely physiological regulation of cellular TH entry within the fetal CNS from 
early development. However, the precise role of TH and each TH transporter during human CNS 
development remains poorly understood but they do not appear to directly impact upon human 
neurodifferentiation. 
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TABLE 1: Characteristics of the thyroid hormone transporters present in the brain. 
Protein Gene Km T4 
(M) 
Km T3 
(M) 
Alternative 
substrates 
Localisation in human brain Localisation in rats and mice References 
MCT8 SLC16A2 4.7 (rat) 4.0 (rat) 
0.86 
(human) 
Unknown Adult and fetus: neurons, blood 
brain barrier, choroid plexus. 
Adult: folliculo-stellate cells of 
anterior pituitary, ependyma of 
3rd ventricle, hypothalamus. 
Adult and fetus/pup: neurons, 
blood brain barrier, choroid 
plexus, tanycytes of 3rd ventricle, 
cerebellar Purkinje cells, cortex, 
striatum, hypothalamus, 
amygdala, hippocampus. 
(Friesema et al., 
2003;Heuer et al., 
2005;Trajkovic et al., 
2007;Roberts et al., 
2008;Wirth et al., 
2009;Kinne et al., 
2010;Fliers et al., 2006) 
MCT10 
(TAT1) 
SLC16A10 *Higher 
than for 
T3 
*Lower 
or the 
same as 
MCT8 
Aromatic 
amino acids 
Unknown Adult: neurons 
Adult rabbits: hypothalamus 
(Friesema et al., 
2008;Ramadan et al., 
2006;Mebis et al., 2009) 
OATP1A2 SLCO1A2 8.0 6.5 Various 
organic 
anions, neutral 
compounds, 
cations 
Adult: blood brain barrier Adult: blood brain barrier (Gao et al., 2000;Reichel et 
al., 1999) 
OATP1C1 
 
SLCO1C1 0.09 ? Bromosulfoph
-thalein, 
oestrogens 
Adult and fetus:  blood brain 
barrier 
Adult and fetus/pup: blood brain 
barrier, choroid plexus, neurons,  
Adult rabbits: hypothalamus 
(Pizzagalli et al., 
2002;Sugiyama et al., 
2003;Roberts et al., 
2008;Tohyama et al., 
2004;Wirth et al., 
2009;Mebis et al., 2009) 
OATP3A1 
variant 1 
SLCO3A1  ? ? Adult: Astrocytes in white 
matter, choroid plexus 
OATP3A1 
variant 2 
SLCO3A1 ? ? 
Prostoglandin 
E1 and E2, 
vasopressin, 
arachidonic 
acid 
Adult:  Neurons in gray and 
white matter, choroid plexus 
Adult: neurons, astroglia  (Huber et al., 2007) 
OATP4A1 SLCO4A1 ? 0.9 Steroid 
conjugates, 
PGE2, 
penicllin 
Adult: cerebral cortex Adult: choroid plexus, neurons,  
cerebral cortex   
(Tamai et al., 
2000;Fujiwara et al., 
2001;Choudhuri et al., 
2003;Wirth et al., 2009) 
LAT1 SLC7A5 Adult: cerebral cortex 
LAT2 SLC7A8 
7.9 0.8 Large neutral 
amino acids Adult: cerebral cortex, neurons 
Fetus: microglia 
Adult and fetus/pup: neurons, 
astrocytes, blood brain barrier, 
choroid plexus 
(Kido et al., 2001;Broer et 
al., 2000;Heckel et al., 
2003;Blondeau et al., 
1993;Wirth et al., 2009) 
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Table 1 legend : 
Only some of the Km values have been determined mainly from studies using Xenopus laevis oocytes: MCT8, LAT-CD98, OATP1A2, OATP4A1.*The 
independent expression of the human MCT8 or MCT10 in COS1 cells both showed a greater preference for T3 than T4 uptake. Whilst MCT10 showed a 
greater ability to transport T3 compared to MCT8, MCT8 was found to be a more potent transporter of T4.  
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Protein Accession 
number 
Forward primer Reverse primer Probe Amplicon 
length (bp) 
Exon-exon 
boundary 
MCT8 NM006517 CAACGCACTTACCGCA
TCTG 
GTAGCCCCAATACA 
ACCAAGAG 
TCCACATACTTCATCA
GGTGTACATAGGGAAC
AAA 
150 3 - 4 
MCT10 NM018593 GATTCATGTCTATACC
CATGACTGTTG 
CACATCATAGGAGCCC
AGTTTGT 
CCCACCCATTGCAGGG
TTACTTCGT 
77 5 - 6 
OATP1A2 NM134431 GTGAACACAGATGATC
TGATCATAACTC 
AACTCCTGCACAAATC
AGAAAGC 
ATGCACCGACCCAACG
AGTGTCAGT 
87 5 - 6 
OATP1C1 NM017435         TTTTGCCTTGGGTATCT
ACACATTAG 
CATGAAGTATCAATCA
AAACTCCAAAAT 
AATAAGAGTTCTTGCA
GGAATCCCAGCTCCA 
90 13 – 14; detects all 
four isoforms 
OATP3A1 
variant 1 
NM013272 CCTTCGTTTGTTGGGCT
TCAT 
GTCAGAGTAGAGGCA
AAGAACTCACT 
CTGGCATCGACTCCAC
CTGCCTG 
282 9 – 10 and splice site 
in exon 10 
OATP3A1 
variant 2 
NM001145044 GAAAAACTATAAACGC
TACATCAAAAACC 
GGTTTTCTCAGTCTCA
ATGTCTTGGTA 
CTCTGTGCTGGTGCTC
AGCCCG 
85 splice site in exon 10 
- exon 11 
OATP4A1 NM016354 GCAGCCACGGAGACG
AA 
AAAGATTCTGAGGGAT
ACAGCTACAGT 
CTCGGTACACCTTCTG
GCCGTCCA 
70 7 - 8 
LAT1 NM003486 AAATGATCAACCCCTA
CAGAAACCT 
ACGTACACCAGCGTCA
CGAT 
CCTGGCCATCATCATC
TCCCTGCC 
73 4 - 5 
LAT2 NM012244 AAATCTGGAGGTGACT
ACTCCTATGTC 
GATCACCAGCACAGCA
ATCC 
AGCCTCAGGAACCCAG
CCAGTCCT 
87 2 - 3 
CD98 NM001012661 TGAGATTGGCCTGGAT
GCA 
GGACTCATCCCACAGC
ATGAC 
CCCTTCCTGGACAGCC
TATGGAGGC 
73 11 -12 
Pou5F1 
(variant 1) 
 
NM_002701 
 
AGAAGGAGAAGCTGG
AGCAAAA 
TGGCAAATTGCTCGAG
TTCTT 
CCGGAGGAGTCCCAGG
ACATCAAA 
78 1-2 
Nestin 
 
NM_006617 GCGGTGGCTCCAAGAC
TTC 
ACTGGGAGCAAAGATC
CAAGAC 
CTTTCAGGACCCCAAG
CTGGAGCTG 
100 3-4 
Neurofila
ment-light  
NM_006158    GACAAGCAGAACGCC
GACAT 
CTTTGTGGTCCTCAATT
CATTTTCTA 
AGCGCTATGCAGGACA
CGATCAACAAA 
75 1-2 
 
TABLE 2: TaqMan® Real-time RT-PCR primers and probes sequences 
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Figure Legends  
Figure 1: The expression of MCT8 and MCT10 in the human fetal cerebral cortex 
Scatter plots showing the relative expression of mRNA (mean ± S.E.M.) encoding the 
monocarboxylate transporters, MCT8 (A) and MCT10 (B), in human fetal cerebral cortex from 7 
to 20 weeks gestation compared with the adult cerebral cortex, given an arbitrary value of 1. 
Western blots demonstrating the specificity of the MCT8 antibody 4790 (C) and MCT10 antibody 
2198 (D). Specificity of the MCT8 antibody (1.6g/ml) was tested in MCT8 null JEG3 cells 
transfected with empty vector (VO) or plasmid encoding human MCT8 (James et al., 2009). 
There are two bands at approximately 60kDa and 120kDa seen in MCT8 transfected cells only 
(C1), consistent with the predicted molecular weights of the MCT8 monomer (63kDa) and 
homodimer (Visser et al., 2009). Both bands disappeared when the MCT8 antibody was 
preabsorbed with excess of blocking peptide (BP; C2). Specificity of the MCT10 antibody 
(0.86g/ml) was determined by transfecting the HTR8/SVNeo cells with empty vector (VO) or 
plasmid encoding human MCT10 (kind gift from Dr Theo Visser, Erasmus University Rotterdam 
(Friesema et al., 2008). A single band at 50kDa was obtained with transfection of MCT10 (D1), 
which disappeared when the antibody was preabsorbed with excess of blocking peptide (D2). 
Immunoblotting for -actin on the same blots were used to assess protein loading. NS = non-
specific band. Representative sections of the fetal forebrain (telencephalon) from 8 to 11 weeks 
gestation (w) showing MCT8 (E1, E3) and MCT10 (F1-2, F4-5) immunoreactivity, which is lost 
with pre-absorption of the primary antibody with the corresponding blocking peptides (BP; E2, 
E4, F3, F6). Microvessels (arrows), undifferentiated CNS cells (unfilled triangles) and a 
differentiating neuron (blackened arrow head) are indicated. Bright fields micrographs taken with 
DIC optics. Scale bar applies to all panels and corresponds to 20m. 
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Figure 2: The expression of the OATPs in the human fetal cerebral cortex  
Scatter plots showing the relative expression of mRNA (mean ± S.E.M.) encoding organic anion 
transporting polypeptides, OATP1A2 (A), OATP1C1 (B), OATP3A1 variants 2 (C) and 1 (D), 
OATP4A1 (E), in human fetal cerebral cortex from 7 to 20 weeks gestation compared with the 
adult cerebral cortex, given an arbitrary value of 1. Statistically significant differences were 
*P<0.05, compared with adults.  
Figure 3: The expression of System L in the human fetal cerebral cortex  
Scatter plots showing the relative expression of mRNA (mean ± S.E.M.) encoding System L 
amino acid transporters, LAT1 (A) and LAT2 (B), and their obligatory associated protein, CD98 
(C), in human fetal cerebral cortex from 7 to 20 weeks gestation compared with the adult cerebral 
cortex, given an arbitrary value of 1. Statistically significant differences were * P<0.05 compared 
with adults, + P<0.05 between gestational age groups.  
Figure 4: Neurodifferentiation marker expression and neuronal morphology in NT2 cells 
with retinoic acid treatment in T3-replete and T3-depleted media  
The relative expression (mean ± S.E.M.) of mRNA encoding the neurodifferentiation markers, 
Pou5F1 (A), nestin (B) and neurofilament (C), with RA-induced neurodifferentiation of NT2 cells 
in T3-replete and T3-depleted media. All data are presented relative to values on Day 0 of RA 
treatment, given an arbitrary value of 1, within each experiment (n=6). Measurements of the 
lengths of primary neurites (D) and the number of primary neurites and branch points (ratio of the 
number of secondary neurites to the number of primary neurites per neuron; E) of neurons 
terminally-differentiated in T3-replete and T3-depleted media are shown. All statistically 
significant differences over time (taking both T3 conditions into account) are indicated as 
follows: a – different from Day 0, b – different from Day 1, c – different from Day 3, d – different 
from Day 7. Numbers represent the following: 1- P<0.05, 2- P<0.01, 3- P<0.001.   
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Figure 5: Thyroid hormone transporter expression and T3 uptake by NT2 cells with 
retinoic acid treatment in T3-replete and T3-depleted media  
TH transporter expression with RA-induced neurodifferentiation of NT2 cells in T3-replete and 
T3-depleted media. All data (mean ± S.E.M.) are presented relative to values on Day 0 of RA 
treatment, given an arbitrary value of 1, within each experiment. Relative expressions of mRNA 
encoding MCT10 (A), LAT2 (B), OATP3A1v2 (C), MCT8 (D), OATP4A1 (E) and LAT1 (F) 
and relative expressions of MCT8 protein analysed by flow cytometry (G), a representative CD98 
Western blot from one experiment (H) and combined CD98 relative densitometry data from 4 
different experiments (I) are shown. Two bands for CD98 (H) were evident until Day 7, the larger 
band representing glycosylated CD98 (gCD98)(Ritchie & Taylor, 2001), and both bands were 
quantified for relative densitometry. Uptake of [125I]T3 after 10 minutes of incubation (J). All 
statistically significant differences over time (taking both T3 conditions into account) are 
indicated as follows: a – different from Day 0, b – different from Day 1, c – different from Day 3, 
d – different from Day 7, e – different from Day 14. Numbers represent the following: 1- P<0.05, 
2- P<0.01, 3- P<0.001. Asterisks indicate significant changes with T3 treatment at the specific 
time points *P<0.05, **P<0.01, ***P<0.001.   
Figure 6: The expression of MCT8 and neurodifferentiation markers in NT2 cells during 
retinoic acid treatment in T3-replete and T3-depleted media following MCT8 knockdown  
The relative expression (mean ± S.E.M.) of mRNA encoding MCT8 (A), Pou5F1 (C), nestin (D) 
and neurofilament (E), from 48 hours (Day 0 of RA treatment) after NT2 transfection with 
MCT8-specific siRNAs (si) or ‘scrambled’ siRNAs (scr) followed by RA-induced 
neurodifferentiation in T3-replete and T3-depleted media. All data is presented relative to values 
for scr on Day 0 of RA treatment, given an arbitrary value of 1, within each experiment (n=4). A 
representative Western blot from one experiment confirming repression of MCT8 in NT2 cells 
transfected with si compared with scr over 7 days of RA treatment (B). Statistically significant 
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differences between si and scr (taking both T3 conditions into account) were #:P<0.00001. All 
statistically significant differences over time (taking both T3 conditions into account) for scr are 
indicated as follows: w – different from Day 0, x – different from Day 1, y – different from Day 
3, z – different from Day 7; and for si are indicated as follows: a – different from Day 0, b – 
different from Day 1, c – different from Day 3, d – different from Day 7. Numbers represent the 
following: 1- P<0.05, 2- P<0.01, 3- P<0.001. 
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